Article
Alcon, over a 2-day span in late June, filed one new drug application (NDA) with the FDA and received approval for another.
Treating systemic inflammation may protect against diabetes
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Study finds faricimab effective for nAMD patients unresponsive to other anti-VEGF treatments
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Case studies highlight advanced techniques in glaucoma management
Tuning out anxiety: the role of music in cataract surgery